Home › Multiple Myeloma › Alabama › Birmingham
Multiple Myeloma clinical trials in Birmingham, AL
18 studies for Multiple Myeloma are looking for participants at sites in and around Birmingham (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
RecruitingPhase 1/2
- University of Alabama At Birmingham Hospital, Birmingham
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 2
- University of Alabama Birmingham, Birmingham
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 3
- Alabama Oncology, Birmingham
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 1/2
- University of Alabama at Birmingham Hospital, Birmingham
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RecruitingPhase 2
- University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
RecruitingPhase 3
- University of Alabama at Birmingham, Birmingham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 2
- University of Alabama at Birmingham, Birmingham
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
RecruitingPhase 1/2
- University of Alabama at Birmingham, Birmingham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
RecruitingPhase 1/2
- Research Site, Birmingham
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
RecruitingPhase 1
- University of Alabama at Birmingham, Birmingham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
RecruitingPhase 2
- University of Alabama at Birmingham, Birmingham
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
RecruitingPhase 1
- University of Alabama at Birmingham, Birmingham
Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
RecruitingPhase 1
- University of Alabama at Birmingham, Birmingham
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
RecruitingPhase 2
- University of Alabama at Birmingham, Birmingham
Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
Recruiting
- Kirklin Clinic of UAB Hospital, Birmingham
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
RecruitingObservational study
- Kirklin Clinic of UAB Hospital, Birmingham
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RecruitingPhase 1
- University of Alabama at Birmingham, Birmingham
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 1/2
- UAB Comprehensive Cancer Center, Birmingham
About Multiple Myeloma
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. Discover symptoms, diagnostic tests, and treatments for myeloma.
More about Multiple Myeloma on MedlinePlus
Multiple Myeloma trials in other cities
- New York City, NY60 studies
- Boston, MA42 studies
- Atlanta, GA41 studies
- Houston, TX38 studies
- Durham, NC37 studies
- Nashville, TN32 studies
- Denver, CO26 studies
- Columbus, OH24 studies
- St. Louis, MO23 studies
- Baldwin Park, CA23 studies
- Rochester, MN23 studies
- Washington, DC22 studies
Other studies in Birmingham
- Cancer (all types)31 studies
- Breast Cancer24 studies
- Obesity24 studies
- Ovarian Cancer23 studies
- Non-Small Cell Lung Cancer22 studies
- Acute Myeloid Leukemia21 studies
- COPD18 studies
- Overweight17 studies
- Cardiovascular Disease17 studies
- Endometrial Cancer16 studies
- Type 2 Diabetes16 studies
- Cystic Fibrosis16 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.